164 related articles for article (PubMed ID: 9678114)
1. Long-term experience of a levonorgestrel-releasing intrauterine system.
Odlind V
Eur J Contracept Reprod Health Care; 1996 Dec; 1(4):319-23. PubMed ID: 9678114
[TBL] [Abstract][Full Text] [Related]
2. Benefit-risk assessment of the levonorgestrel intrauterine system in contraception.
Backman T
Drug Saf; 2004; 27(15):1185-204. PubMed ID: 15588115
[TBL] [Abstract][Full Text] [Related]
3. Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants.
Sivin I
Drug Saf; 2003; 26(5):303-35. PubMed ID: 12650633
[TBL] [Abstract][Full Text] [Related]
4. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
Luukkainen T; Toivonen J
Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
[TBL] [Abstract][Full Text] [Related]
5. Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women.
Lehtovirta P; Paavonen J; Heikinheimo O
Contraception; 2007 Jan; 75(1):37-9. PubMed ID: 17161122
[TBL] [Abstract][Full Text] [Related]
6. Use of the levonorgestrel-releasing intrauterine system: an Austrian perspective.
Concin H; Bösch H; Hintermüller P; Hohlweg T; Mursch-Edlmayr G; Pinnisch B; Schmidl-Amann S; Schulz-Greinwald G; Unterlerchner D; Wagner T; Mattle V; Wildt L; Fiala C
Curr Opin Obstet Gynecol; 2009 Nov; 21 Suppl 1():S1-9. PubMed ID: 20019650
[TBL] [Abstract][Full Text] [Related]
7. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE
Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
[TBL] [Abstract][Full Text] [Related]
8. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
Pakarinen PI; Suvisaari J; Luukkainen T; Lähteenmäki P
Fertil Steril; 1997 Jul; 68(1):59-64. PubMed ID: 9207585
[TBL] [Abstract][Full Text] [Related]
9. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system.
Eisenberg DL; Schreiber CA; Turok DK; Teal SB; Westhoff CL; Creinin MD;
Contraception; 2015 Jul; 92(1):10-6. PubMed ID: 25934164
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices.
Toivonen J; Luukkainen T; Allonen H
Obstet Gynecol; 1991 Feb; 77(2):261-4. PubMed ID: 1899136
[TBL] [Abstract][Full Text] [Related]
11. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.
Suvisaari J; Lähteenmäki P
Contraception; 1996 Oct; 54(4):201-8. PubMed ID: 8922872
[TBL] [Abstract][Full Text] [Related]
12. IUDs and ectopic pregnancy.
Sivin I
Contraception; 1995 Nov; 52(5):321-2. PubMed ID: 8585891
[No Abstract] [Full Text] [Related]
13. Heterotopic cesarean scar pregnancy associated with a levonorgestrel-releasing intrauterine device.
Dueñas-Garcia OF; Young C
Int J Gynaecol Obstet; 2011 Aug; 114(2):153-4. PubMed ID: 21679948
[No Abstract] [Full Text] [Related]
14. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development.
Shaamash AH; Sayed GH; Hussien MM; Shaaban MM
Contraception; 2005 Nov; 72(5):346-51. PubMed ID: 16246660
[TBL] [Abstract][Full Text] [Related]
15. Levonorgestrel-releasing (20 microgram/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives.
French RS; Cowan FM; Mansour D; Higgins JP; Robinson A; Procter T; Morris S; Guillebaud J
BJOG; 2000 Oct; 107(10):1218-25. PubMed ID: 11028571
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial.
Gemzell-Danielsson K; Apter D; Hauck B; Schmelter T; Rybowski S; Rosen K; Nelson A
PLoS One; 2015; 10(9):e0135309. PubMed ID: 26378938
[TBL] [Abstract][Full Text] [Related]
17. A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents.
Gemzell-Danielsson K; Buhling KJ; Dermout SM; Lukkari-Lax E; Montegriffo E; Apter D
Contraception; 2016 Jun; 93(6):507-12. PubMed ID: 26872720
[TBL] [Abstract][Full Text] [Related]
18. Jaydess® levonorgestrel intrauterine system.
Melvin L; Scott J; Craik J
J Fam Plann Reprod Health Care; 2014 Jul; 40(3):165-9. PubMed ID: 24939481
[No Abstract] [Full Text] [Related]
19. Intrauterine devices: an effective alternative to oral hormonal contraception.
Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
[TBL] [Abstract][Full Text] [Related]
20. The levonorgestrel-releasing intrauterine system in modern gynaecology.
McGavigan CJ; Owen P
Br J Hosp Med (Lond); 2005 Oct; 66(10):574-7. PubMed ID: 16255257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
